Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Prockop

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
Bone Marrow Transplantation|May 12, 2020
Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplantVanessa A Fabrizio, Nancy A Kernan, Farid Boulad, et al.
The Lancet. Oncology|February 3, 2024
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trialKris Michael Mahadeo, Robert Baiocchi, Amer Beitinjaneh, et al.
Pediatric Rheumatology Online Journal|January 5, 2024
Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & EuropeAlexei A Grom, Scott W Canna, Rolla F Abu-Arja, et al.
Cytotherapy|March 14, 2024
Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering CommitteeTami D John, Gabriela Maron, Allistair Abraham, et al.
Blood|November 5, 2020
CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validationCoco de Koning, Susan Prockop, Ichelle van Roessel, et al.
Blood Advances|April 16, 2024
Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocolSarah Nikiforow, Jennifer S Whangbo, Ran Reshef, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2015
Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood TransplantationStephen Harnicar, Doris M Ponce, Patrick Hilden, et al.
Nature Reviews. Rheumatology|July 2, 2025
CAR T cell therapy for children with rheumatic disease: the time is nowHolly Wobma, Stacy P Ardoin, Challice L Bonifant, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 15, 2011
Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantationDoris M Ponce, Junting Zheng, Anne Marie Gonzales, et al.
Blood Advances|November 17, 2021
Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantationMadhavi Lakkaraja, Michael Scordo, Audrey Mauguen, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
Bone Marrow Transplantation|May 12, 2020
Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplantVanessa A Fabrizio, Nancy A Kernan, Farid Boulad, et al.
The Lancet. Oncology|February 3, 2024
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trialKris Michael Mahadeo, Robert Baiocchi, Amer Beitinjaneh, et al.
Pediatric Rheumatology Online Journal|January 5, 2024
Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & EuropeAlexei A Grom, Scott W Canna, Rolla F Abu-Arja, et al.
Cytotherapy|March 14, 2024
Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering CommitteeTami D John, Gabriela Maron, Allistair Abraham, et al.
Blood|November 5, 2020
CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validationCoco de Koning, Susan Prockop, Ichelle van Roessel, et al.
Blood Advances|April 16, 2024
Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocolSarah Nikiforow, Jennifer S Whangbo, Ran Reshef, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2015
Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood TransplantationStephen Harnicar, Doris M Ponce, Patrick Hilden, et al.
Nature Reviews. Rheumatology|July 2, 2025
CAR T cell therapy for children with rheumatic disease: the time is nowHolly Wobma, Stacy P Ardoin, Challice L Bonifant, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 15, 2011
Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantationDoris M Ponce, Junting Zheng, Anne Marie Gonzales, et al.
Blood Advances|November 17, 2021
Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantationMadhavi Lakkaraja, Michael Scordo, Audrey Mauguen, et al.
Pageof 7